Author Archive: Jason Corum

Jason Corum

Jason is the director of web and new media with the Biotechnology Industry Organization (BIO). Prior to joining BIO in March 2011, he was the online communications manager for World Food Program USA and an online communications specialist with the Brookings Institution.

Jason is originally from Evergreen Park, Ill. and still thinks that Chicago is the best food city in the nation.  He spends his free time volunteering with the DC Books to Prisons Project, watching movies and reading comics.

Latest Posts

FDASIA: A Step Forward for Patients

fdasia-panel

Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act (FDASIA) which included a re-authorization of the Prescription Drug User Fee Act (PDUFA). PDUFA provides essential funding to the FDA by authorizing the agency to charge user fees to companies seeking to have products reviewed. Originally enacted in 1992, it must be reauthorized every 5 years. Sara Radcliffe, executive vice president of health at BIO, moderated a panel of experts and advocates Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

It Takes a Village: The New Pharma-VC Model for Biotech Investing

bif-hall

High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in recent months, pooling resources and expertise in an attempt to source and develop the most successful drugs. BIO Executive Vice President Alan Eisenberg moderated It Takes a Village: The New Pharma-VC Model for Biotech Investing, a panel discussion about these new funding models, during the opening plenary session at the 2012 BIO Investor Forum. In the past, venture capital could Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Technology Transfer Symposium: Funding that First $2 Million

2-mill

With creative funding schemes picking up steam and nontraditional funders taking an interest in biotech, what can universities and start-ups expect in their right first-round financing structure? At the BIO Technology Transfer Symposium, a panel examined various funding sources as well as the factors that influence investment decisions and the ins and outs of early stage financing deals. William Tucker, executive director, Innovation Alliances and Services, University of California Office of the President, moderated a Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Cancer Stem Cell Therapy: Real Or Just Hype?

Stem Cell Therapy

Also known as tumor-initiating cells, cancer stem cells (CSC) have unique capability endemic to stem cells of self-renewal and differentiation, thereby causing tumor relapse and/or metastatis. While traditional cancer treatments focus on tumor shrinkage, it’s a distinct possibility that these agents do not effectively destroy all of the CSCs, causing the tumor to reappear. The CSC theory is relatively new, so the treatment pipeline is still in its early stages. Nathan Sadeghi-Nejad, a contributor to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Official Blogger Roundup

Official Blogger

Want to know what’s happening at the 2012 BIO International Convention? Find out from our BIO Official Bloggers! Cross Border Biotech – Now on Video, The Cross-Border Biotech Blog Alberta, BIO, Biotech and Business, GenomeAlberta The Long and Sometimes Winding Road to Humanitarian of the Year, GenomeAlberta Alberta Company Helps Diabetics Put Their Best Food Forward, GenomeAlberta Metabolomics Technology Tackles Cancer, GenomeAlberta Pre-competitive collaboration brings medicines to patients, LillyPad Widespread praise for US drug bill, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,